Cargando…

Urinary Pharmacokinetic and Pharmacodynamic Profiles of Fosfomycin against Extended-Spectrum β-Lactamase-Producing Escherichia coli with Canine Ex Vivo Modeling: A Pilot Study

Fosfomycin is a candidate drug for extended-spectrum β-lactamase (ESBL)-producing bacteria, but its efficacy is yet to be investigated in dogs. This study investigated the urinary pharmacokinetic/pharmacodynamic (PK/PD) profile of fosfomycin orally administered at 80 mg/kg to six healthy dogs to ass...

Descripción completa

Detalles Bibliográficos
Autores principales:	Harada, Kazuki, Shimizu, Takae, Kawaguchi, Koji, Furuhashi, Takeshi, Ishihara, Genki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7277591/ https://www.ncbi.nlm.nih.gov/pubmed/32380640 http://dx.doi.org/10.3390/antibiotics9050230

Ejemplares similares

Assessment of urinary pharmacokinetic and pharmacodynamic profiles of faropenem against extended-spectrum β-lactamase-producing Escherichia coli with canine ex vivo modelling: a pilot study
por: Harada, Kazuki, et al.
Publicado: (2019)

Deciphering pharmacokinetics and pharmacodynamics of fosfomycin
por: Rodríguez-Gascón, Alicia, et al.
Publicado: (2019)

Antimicrobial Susceptibilities of Urinary Extended-spectrum β-lactamase Escherichia coli to Fosfomycin
por: Saeed, Nermin Kamal, et al.
Publicado: (2021)

Nitrofurantoin and Fosfomycin for Extended Spectrum Beta-lactamases Producing Escherichia coli and Klebsiella pneumoniae
por: Tulara, Neeraj Kumar
Publicado: (2018)

Pharmacokinetics and Pharmacodynamics of Fosfomycin and Its Activity against Extended-Spectrum-β-Lactamase-, Plasmid-Mediated AmpC-, and Carbapenemase-Producing Escherichia coli in a Murine Urinary Tract Infection Model
por: Zykov, Ilya Nikolaevich, et al.
Publicado: (2018)

Pharmacokinetic–pharmacodynamic analysis of cefmetazole against extended-spectrum β-lactamase-producing Enterobacteriaceae in dogs using Monte Carlo Simulation
por: Kusumoto, Mizuki, et al.
Publicado: (2023)

Mutant prevention concentration of orbifloxacin: comparison between Escherichia coli, Pseudomonas aeruginosa, and Staphylococcus pseudintermedius of canine origin
por: Shimizu, Takae, et al.
Publicado: (2013)

Determination of Extended-Spectrum β-Lactamases and AmpC Production in Uropathogenic Isolates of Escherichia coli and Susceptibility to Fosfomycin
por: Gupta, Varsha, et al.
Publicado: (2013)

Resistance to fosfomycin is increasing and is significantly associated with extended-spectrum β-lactamase-production in urinary isolates of Escherichia coli
por: Ríos, Esther, et al.
Publicado: (2022)

Characterization of Fosfomycin Resistant Extended-Spectrum β-Lactamase-Producing Escherichia coli Isolates from Human and Pig in Taiwan
por: Tseng, Sung-Pin, et al.
Publicado: (2015)

135 Fosfomycin Susceptibilities Among Uropathogenic Extended Spectrum Beta-Lactamase-producing Enterobacteriacea
por: Abbo, Lilian, et al.
Publicado: (2014)

Antibacterial effect evaluation of moxalactam against extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae with in vitro pharmacokinetics/pharmacodynamics simulation
por: Huang, Chen, et al.
Publicado: (2018)

Dose Optimization of Combined Linezolid and Fosfomycin against Enterococcus by Using an In Vitro Pharmacokinetic/Pharmacodynamic Model
por: Mao, Jun, et al.
Publicado: (2021)

Chronic prostatitis caused by extended-spectrum β-lactamase-producing Escherichia coli managed using oral fosfomycin—A case report
por: Almeida, Francisco, et al.
Publicado: (2019)

Studies on Virulence and Extended-Spectrum β-Lactamase-Producing Uropathogenic Escherichia coli Isolates and Therapeutic Effect of Fosfomycin in Acute Pyelonephritis Mice
por: Zhang, Lingchun, et al.
Publicado: (2022)

Pharmacodynamics of Ceftriaxone, Ertapenem, Fosfomycin and Gentamicin in Neisseria gonorrhoeae
por: Gubenšek, Urša, et al.
Publicado: (2022)

Fosfomycin susceptibility among multidrug-resistant, extended-spectrum beta-lactamase-producing, carbapenem-resistant uropathogens
por: Banerjee, Sayantan, et al.
Publicado: (2017)

Synergistic Activity of Colistin/Fosfomycin Combination against Carbapenemase-Producing Klebsiella pneumoniae in an In Vitro Pharmacokinetic/Pharmacodynamic Model
por: Wang, Jin, et al.
Publicado: (2018)

In vitro Pharmacokinetics/Pharmacodynamics Evaluation of Fosfomycin Combined with Amikacin or Colistin against KPC2-Producing Klebsiella pneumoniae
por: Yu, Wei, et al.
Publicado: (2017)

Pharmacokinetic/Pharmacodynamic Analysis of Oral Calcium Fosfomycin: Are Urine Levels Sufficient to Ensure Efficacy for Urinary Tract Infections?
por: Rodríguez-Gascón, Alicia, et al.
Publicado: (2023)

Characterization of Extended-Spectrum β-Lactamase Genes of Shigella flexneri Isolates With Fosfomycin Resistance From Patients in China
por: Liu, Yanyan, et al.
Publicado: (2017)

Experience with fosfomycin in the treatment of complicated urinary tract infections caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae
por: Bielen, Luka, et al.
Publicado: (2019)

Pharmacokinetics of fosfomycin in patients with prophylactic treatment for recurrent Escherichia coli urinary tract infection
por: Kuiper, Sander G, et al.
Publicado: (2020)

Post-antibiotic effect of orbifloxacin against Escherichia coli and Pseudomonas aeruginosa isolates from dogs
por: Harada, Kazuki, et al.
Publicado: (2012)

611. Fosfomycin Resistance of Multidrug-Resistant Escherichia coli and Mechanisms of Fosfomycin Resistance
por: Seok, Hyeri, et al.
Publicado: (2019)

2261. Oral Fosfomycin for Treatment of Urinary Tract Infections Due to Extended-Spectrum β-Lactamase and Carbapenem-Resistant Enterobacteriaceae
por: Hefler, Jade L, et al.
Publicado: (2019)

Pharmacokinetic/Pharmacodynamic Evaluation of Aztreonam/Amoxicillin/Clavulanate Combination against New Delhi Metallo-β-Lactamase and Serine-β-Lactamase Co-Producing Escherichia coli and Klebsiella pneumoniae
por: Zhang, Jiayuan, et al.
Publicado: (2023)

The Pre-clinical Toolbox of Pharmacokinetics and Pharmacodynamics: in vitro and ex vivo Models
por: Herrera, Carolina
Publicado: (2019)

Fosfomycin Resistance in Escherichia coli, Pennsylvania, USA
por: Alrowais, Hind, et al.
Publicado: (2015)

Fosfomycin versus meropenem in bacteraemic urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli (FOREST): study protocol for an investigator-driven randomised controlled trial
por: Rosso-Fernández, Clara, et al.
Publicado: (2015)

Phenotypic and Molecular Characterization of Antimicrobial Resistance in Klebsiella spp. Isolates from Companion Animals in Japan: Clonal Dissemination of Multidrug-Resistant Extended-Spectrum β-Lactamase-Producing Klebsiella pneumoniae
por: Harada, Kazuki, et al.
Publicado: (2016)

Plasma and Urine Pharmacokinetics of Oral Fosfomycin Tromethamine in Dogs
por: Jariyapamornkoon, Nattha, et al.
Publicado: (2023)

Pharmacokinetic and Pharmacodynamic Integration and Modeling of Enrofloxacin in Swine for Escherichia coli
por: Wang, Jianyi, et al.
Publicado: (2016)

Pharmacokinetic–Pharmacodynamic Modeling of Enrofloxacin Against Escherichia coli in Broilers
por: Sang, KaNa, et al.
Publicado: (2016)

976. Population Pharmacokinetic/Pharmacodynamic (PK/PD) Target Attainment Analysis of Intravenous Fosfomycin for Treatment of Multidrug-Resistant Gram-Negative Bacterial Infections
por: Wangchinda, Walaiporn, et al.
Publicado: (2023)

Pharmacokinetics and Pharmacodynamics with Extended Dosing of CC-486 in Patients with Hematologic Malignancies
por: Laille, Eric, et al.
Publicado: (2015)

Effect of Glycerol on Fosfomycin Activity against Escherichia coli
por: Ortiz-Padilla, Miriam, et al.
Publicado: (2022)

Fosfomycin, interesting alternative drug for treatment of urinary tract infections created by multiple drug resistant and extended spectrum β-lactamase producing strains
por: Yeganeh-Sefidan, Fatemeh, et al.
Publicado: (2016)

Pharmacokinetic/Pharmacodynamic Determination and Preclinical Pharmacokinetics of the β-Lactamase Inhibitor ETX1317 and Its Orally Available Prodrug ETX0282
por: O’Donnell, John, et al.
Publicado: (2020)

IV and oral fosfomycin pharmacokinetics in neonates with suspected clinical sepsis
por: Kane, Zoe, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_fjkrtiekbfcej85jdstsqq60da